News
Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion ... Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA ...
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South ... into a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and ...
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...
On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA ... a reversible alternative to CRISPR. The collaboration complements Lilly’s existing genetic ...
2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results